⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747073 | 0.78 | LDHA (0.33) | — | |
| SCHEMBL9361809 | 0.72 | — | — | |
| SCHEMBL31045 | 0.72 | — | — | |
| SCHEMBL9063447 | 0.71 | FFAR3 (0.35) | — | |
| SCHEMBL17393587 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL1569396 | 0.69 | — | — | |
| SCHEMBL2201780 | 0.69 | — | — | |
| SCHEMBL28284985 | 0.69 | — | — | |
| SCHEMBL15517291 | 0.69 | — | — | |
| SCHEMBL1252799 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-6204220-B1 | AS HERBICIDES FOR CONTROLLING UNWANTED VEGETATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-03-20 | — | — | US | claimed |
| US-20230067928-A1 | METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE | UNIV CORNELL (US) | 2023-03-02 | — | — | US | disclosed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-11397182-B2 | Methods for prognosing and preventing metastatic liver disease | CORNELL UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| US-20040019921-A1 | Non-human mammal with disrupted or modified MIF gene, and uses thereof | FINGERLE-ROWSON GUNTER R (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2003047558-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS | GENSET S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| US-6204220-B1 | AS HERBICIDES FOR CONTROLLING UNWANTED VEGETATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-03-20 | — | — | US | disclosed |
| WO-2001009118-A2 | DITHIOLTHIONE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND FOR MEMORY ENHANCEMENT | PRENDERGAST PATRICK T (IE) | 2001-02-08 | — | — | WO | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |